VA/DoD Clinical Practice Guidelines
Suicide Risk Behavior FDA Warning
UPDATE - September 15, 2015
CLOZAPINE: Drug Safety Communication - FDA Modifies Monitoring for Neutropenia; Approves New Shared REMS Program
FDA is making changes to the requirements for monitoring, prescribing, dispensing, and receiving the schizophrenia medicine clozapine, to address continuing safety concerns and current knowledge about a serious blood condition called severe neutropenia. Severe neutropenia is a dangerously low number of neutrophils, white blood cells that help fight infections. Severe neutropenia can be life-threatening. Link to Clozapine Notice